Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ:IPXL), today announced that it has initiated a multinational Phase III trial of its late-stage drug candidate IPX066 in advanced Parkinson’s disease (PD) patients.

27 Oct 2009

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

FDA issues emergency use authorization for peramivir anti-viral drug

BioCryst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

BD to acquire HandyLab

BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.

From BD (Becton, Dickinson and Company) 24 Oct 2009

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

22 Oct 2009

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Halozyme Therapeutics, Inc. today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro. The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations.

22 Oct 2009

Unilife Medical Solutions to market its products at pharmaceutical industry event

Unilife Medical Solutions Limited today announced it will be exhibiting at two upcoming pharmaceutical trade shows and conferences.

22 Oct 2009

Optimized mouthpiece design reduces wastage of medication

Researchers have developed an optimized mouthpiece design to aid efficient drug delivery to the lungs by reducing the amount of medication wasted as it passes through the mouthpiece of an aerosol inhaler.

22 Oct 2009

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche’s anticancer biologic, Herceptin (trastuzumab).

22 Oct 2009

Study results of PTH1-34 oral parathyroid hormone presented

Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere’s proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.

22 Oct 2009

Bionate II PCU launched by DSM Biomedical

DSM PTG, part of DSM Biomedical, a global leader in biomedical materials science, today announced the availability of Bionate® II PCU, a versatile medical polymer with built-in surface technology designed for chronic implants.

21 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled.

21 Oct 2009

U.S. Pharmacopeial fellowships awarded to 6 students

New research focused on the quality of key medicines and their use as well as increasingly popular botanicals is being sponsored by the U.S. Pharmacopeial (USP) Convention under its 2009� Fellowship Program.

21 Oct 2009

Controlled formation of patchy particles may serve as drug-delivery vehicles to combat disease

Physicists, chemists and engineers at the University of Pennsylvania have demonstrated a novel method for the controlled formation of patchy particles, using charged, self-assembling molecules that may one day serve as drug-delivery vehicles to combat disease and perhaps be used in small batteries that store and release charge.

21 Oct 2009

Cambrex wins the CPhI Innovation Award for its Continuous-Flow Microwave-Assisted Organic Synthesis technology

Cambrex Corporation announced today that it won the Silver Innovation Award at the 2009 CPhI Event for its Continuous-Flow Microwave-Assisted Organic Synthesis (CFMAOS) technology. The award was accepted by Dr. Jayne E. Muir (Market Research & New Technologies - Europe), who presented the technology to a panel of judges at this important pharmaceutical ingredients exhibition in Madrid, Spain on October 13, 2009.

21 Oct 2009

Covalon and Bard sign license agreement; Bard to apply Covalon's technology on its products

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSX VENTURE:COV), an advanced medical products company, announced that it has signed a License Agreement as well as a Services and Supply Agreement with a division of C. R. Bard, Inc.

20 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Drug Delivery News and Research

Further Reading

Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients

Japanese Patent granted for Pharmalink AB's Nefecon

FDA issues emergency use authorization for peramivir anti-viral drug

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

BD to acquire HandyLab

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Unilife Medical Solutions to market its products at pharmaceutical industry event

Optimized mouthpiece design reduces wastage of medication

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Study results of PTH1-34 oral parathyroid hormone presented

Bionate II PCU launched by DSM Biomedical

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

U.S. Pharmacopeial fellowships awarded to 6 students

Controlled formation of patchy particles may serve as drug-delivery vehicles to combat disease

Cambrex wins the CPhI Innovation Award for its Continuous-Flow Microwave-Assisted Organic Synthesis technology

Covalon and Bard sign license agreement; Bard to apply Covalon's technology on its products

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News